Our Blog Melanoma360

Featured image for “President’s Letter | September 2022”
09/27/2022

President’s Letter | September 2022

From the Desk of Samantha Guild Leaves are falling, pumpkins are out, football is on TV, and the kids are…
Blog - Melanoma360
President's Letter
Featured image for “AIM Welcomes Ann Garst Taylor as New Director of Community Engagement”
09/27/2022

AIM Welcomes Ann Garst Taylor as New Director of Community Engagement

By Mara Klecker Ann Garst Taylor, AIM at Melanoma’s new Director of Community Engagement, has nearly 30 years of volunteer…
Blog - Melanoma360
Uncategorized
Featured image for “Bristol Myers Squibb Receives European Commission Approval for LAG-3-Blocking Antibody Combination, Opdualag , for the Treatment of Unresectable or Metastatic Melanoma with Tumor Cell PD-L1 Expression < 1%”
09/16/2022

Bristol Myers Squibb Receives European Commission Approval for LAG-3-Blocking Antibody Combination, Opdualag , for the Treatment of Unresectable or Metastatic Melanoma with Tumor Cell PD-L1 Expression < 1%

(NEWS PROVIDED BY  Bristol Myers Squibb, September 16, 2022, ) Opdualag is a first-in-class, fixed-dose dual immunotherapy combination treatment of the…
Blog - Melanoma360
Breaking News
Featured image for “Spirituality and Cancer Care With Michael Eselun, BCC”
09/13/2022

Spirituality and Cancer Care With Michael Eselun, BCC

When faced with a cancer diagnosis, some patients rely on their spirituality to cope and find meaning behind the experience.…
Blog - Melanoma360
Podcast
Featured image for “ESMO: TIL therapy improves on Yervoy in melanoma trial”
09/13/2022

ESMO: TIL therapy improves on Yervoy in melanoma trial

(NEWS PROVIDED BY  Pharmaphorum, September 11, 2022, Phil Taylor) A personalised cell therapy based on tumour-infiltrating lymphocyte (TIL) cells has…
Blog - Melanoma360
Breaking News
Featured image for “Regeneron Reports Fianlimab plus Libtayo Showed Above 60% Response Rate in Patients with Advanced Melanoma Naïve to PD-1 or PD-L1 Inhibitors”
09/12/2022

Regeneron Reports Fianlimab plus Libtayo Showed Above 60% Response Rate in Patients with Advanced Melanoma Naïve to PD-1 or PD-L1 Inhibitors

(NEWS PROVIDED BY Regeneron Pharmaceuticals, Inc. Sep 12, 2022, 02:30 ET) Positive clinical data presented in a mini-oral session at ESMO…
Blog - Melanoma360
Breaking News
Featured image for “Pembrolizumab in the Neoadjuvant Setting Benefits EFS in High-Risk Melanoma”
09/11/2022

Pembrolizumab in the Neoadjuvant Setting Benefits EFS in High-Risk Melanoma

Neoadjuvant IO Boosts High-Risk Melanoma EFS Results from the phase 2 SWOG S1801 study show that for patients given pembrolizumab…
Blog - Melanoma360
Breaking News
Featured image for “Survivor Spotlight: Erich & Jenn Djordjevic”
09/06/2022

Survivor Spotlight: Erich & Jenn Djordjevic

By Mara Klecker Note: Erich passed away on September 28th, 2022, the same week his story ran in our newsletter.…
Blog - Melanoma360
Friends, Family, & Caregivers
Featured image for “Survivor Spotlight: Bev Johnson, Mucosal Melanoma Survivor”
09/06/2022

Survivor Spotlight: Bev Johnson, Mucosal Melanoma Survivor

By Mara Klecker Bev Johnson figured the abnormal bleeding she was experiencing was a side effect of her IUD losing…
Blog - Melanoma360
Survivor Stories
Featured image for “The Trouble with Toxic Positivity With Whitney Goodman, LMFT, Author”
08/09/2022

The Trouble with Toxic Positivity With Whitney Goodman, LMFT, Author

When going through difficulty, many people turn to friends and family for support. But what happens when those people dismiss…
Blog - Melanoma360
Podcast
09/27/2022

President’s Letter | September 2022

From the Desk of Samantha Guild Leaves are falling, pumpkins are out, football is on TV, and the kids are…
Featured image for “President’s Letter | September 2022”
Blog - Melanoma360
 | 
President's Letter
09/27/2022

AIM Welcomes Ann Garst Taylor as New Director of Community Engagement

By Mara Klecker Ann Garst Taylor, AIM at Melanoma’s new Director of Community Engagement, has nearly 30 years of volunteer…
Featured image for “AIM Welcomes Ann Garst Taylor as New Director of Community Engagement”
Blog - Melanoma360
 | 
Uncategorized
09/16/2022

Bristol Myers Squibb Receives European Commission Approval for LAG-3-Blocking Antibody Combination, Opdualag , for the Treatment of Unresectable or Metastatic Melanoma with Tumor Cell PD-L1 Expression < 1%

(NEWS PROVIDED BY  Bristol Myers Squibb, September 16, 2022, ) Opdualag is a first-in-class, fixed-dose dual immunotherapy combination treatment of the…
Featured image for “Bristol Myers Squibb Receives European Commission Approval for LAG-3-Blocking Antibody Combination, Opdualag , for the Treatment of Unresectable or Metastatic Melanoma with Tumor Cell PD-L1 Expression < 1%”
Blog - Melanoma360
 | 
Breaking News
09/13/2022

Spirituality and Cancer Care With Michael Eselun, BCC

When faced with a cancer diagnosis, some patients rely on their spirituality to cope and find meaning behind the experience.…
Featured image for “Spirituality and Cancer Care With Michael Eselun, BCC”
Blog - Melanoma360
 | 
Podcast
09/13/2022

ESMO: TIL therapy improves on Yervoy in melanoma trial

(NEWS PROVIDED BY  Pharmaphorum, September 11, 2022, Phil Taylor) A personalised cell therapy based on tumour-infiltrating lymphocyte (TIL) cells has…
Featured image for “ESMO: TIL therapy improves on Yervoy in melanoma trial”
Blog - Melanoma360
 | 
Breaking News
09/12/2022

Regeneron Reports Fianlimab plus Libtayo Showed Above 60% Response Rate in Patients with Advanced Melanoma Naïve to PD-1 or PD-L1 Inhibitors

(NEWS PROVIDED BY Regeneron Pharmaceuticals, Inc. Sep 12, 2022, 02:30 ET) Positive clinical data presented in a mini-oral session at ESMO…
Featured image for “Regeneron Reports Fianlimab plus Libtayo Showed Above 60% Response Rate in Patients with Advanced Melanoma Naïve to PD-1 or PD-L1 Inhibitors”
Blog - Melanoma360
 | 
Breaking News
09/11/2022

Pembrolizumab in the Neoadjuvant Setting Benefits EFS in High-Risk Melanoma

Neoadjuvant IO Boosts High-Risk Melanoma EFS Results from the phase 2 SWOG S1801 study show that for patients given pembrolizumab…
Featured image for “Pembrolizumab in the Neoadjuvant Setting Benefits EFS in High-Risk Melanoma”
Blog - Melanoma360
 | 
Breaking News
09/06/2022

Survivor Spotlight: Erich & Jenn Djordjevic

By Mara Klecker Note: Erich passed away on September 28th, 2022, the same week his story ran in our newsletter.…
Featured image for “Survivor Spotlight: Erich & Jenn Djordjevic”
Blog - Melanoma360
 | 
Friends, Family, & Caregivers
09/06/2022

Survivor Spotlight: Bev Johnson, Mucosal Melanoma Survivor

By Mara Klecker Bev Johnson figured the abnormal bleeding she was experiencing was a side effect of her IUD losing…
Featured image for “Survivor Spotlight: Bev Johnson, Mucosal Melanoma Survivor”
Blog - Melanoma360
 | 
Survivor Stories
08/09/2022

The Trouble with Toxic Positivity With Whitney Goodman, LMFT, Author

When going through difficulty, many people turn to friends and family for support. But what happens when those people dismiss…
Featured image for “The Trouble with Toxic Positivity With Whitney Goodman, LMFT, Author”
Blog - Melanoma360
 | 
Podcast